Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND

Status:
Active, not recruiting

Trial end date:
2024-06-28

Target enrollment:

Participant gender:

The purpose of this extension trial is to evaluate the long-term safety of tralokinumab.

Phase 3

LEO Pharma

Antibodies, Monoclonal